Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL659733 | 0.89 | L3MBTL1 (0.54) | POLBL3MBTL1CYP2C9CYP2C19KMT2A | |
| SCHEMBL656058 | 0.84 | PDPK1 (0.62) | POLBPDPK1L3MBTL1CYP2C9CYP2C19 | |
| SCHEMBL10256955 | 0.80 | POLB (0.72) | POLBPDPK1L3MBTL1CYP2C9CYP2C19 | |
| SCHEMBL657707 | 0.79 | PDPK1 (0.56) | POLBPDPK1L3MBTL1CYP2C9CYP2C19 | |
| SCHEMBL658265 | 0.79 | PDPK1 (0.72) | POLBPDPK1L3MBTL1CYP2C9CYP2C19 | |
| SCHEMBL2141563 | 0.79 | PDPK1 (0.63) | POLBPDPK1L3MBTL1CYP2C9CYP2C19 | |
| SCHEMBL657310 | 0.78 | CYP2C9 (0.73) | POLBPDPK1L3MBTL1CYP2C9CYP2C19 | |
| SCHEMBL657492 | 0.78 | PDPK1 (0.76) | POLBPDPK1L3MBTL1CYP2C9CYP2C19 | |
| SCHEMBL657374 | 0.78 | KMT2A (0.72) | POLBPDPK1L3MBTL1CYP2C9CYP2C19 | |
| SCHEMBL2142802 | 0.78 | PDPK1 (0.55) | POLBPDPK1L3MBTL1CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2349999-B1 | ALLOSTERIC PROTEIN KINASE MODULATORS | UNIV SAARLAND (DE) | 2016-01-27 | — | — | EP | disclosed |
| US-8912186-B2 | Allosteric protein kinase modulators | UNIVERSITAET DES SAARLANDES (DE) | 2014-12-16 | — | — | US | disclosed |
| US-20120046307-A1 | ALLOSTERIC PROTEIN KINASE MODULATORS | UNIVERSITAET DES SAARLANDES (DE) | 2012-02-23 | — | — | US | disclosed |
| EP-2349999-A1 | ALLOSTERIC PROTEIN KINASE MODULATORS | Universität des Saarlandes (DE) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010043711-A1 | ALLOSTERIC PROTEIN KINASE MODULATORS | UNIVERSITAET DES SAARLANDES (DE) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046307-A1 | ALLOSTERIC PROTEIN KINASE MODULATORS | AURKC, AURKA, AURKB | POLB 4008/4885PDPK1 109/4885L3MBTL1 3302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.